Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: abacavir
BRAND NAME: Ziagen
DRUG CLASS AND MECHANISM: Abacavir is an oral medication that is used for the treatment of infections with the human immunodeficiency virus (HIV). It is in a class of drugs called reverse transcriptase inhibitors which also includes zalcitabine (Hivid), zidovudine (Retrovir), didanosine (Videx), lamivudine (Epivir), emtricitabine (Emtriva), and stavudine (Zerit). During infection with HIV, the HIV virus multiplies within the body's cells. The newly-formed viruses then are released from the cells and spread throughout the body where they infect other cells. In this manner, the infection continually spreads to new, uninfected cells that the body is continually producing, and HIV infection is perpetuated. When producing new viruses, the HIV virus must manufacture new DNA for each virus. Reverse transcriptase is the enzyme that the virus uses to form this new DNA. Specifically, abacavir is converted within the body to its active form (carbovir triphosphate). This active form is similar to a compound (deoxyguanosine triphosphate), a chemical that is required by the HIV virus to make new DNA. The reverse transcriptase uses carbovir triphosphate instead of deoxyguanosine triphosphate for making DNA, and it is the carbovir triphosphate that interferes with the reverse transcriptase. Abacavir does not kill existing HIV virus, and it is not a cure for HIV. The FDA approved abacavir in December 1998.
GENERIC AVAILABLE: No
PREPARATIONS: Tablets: 300 mg; oral solution: 20 mg/ml
STORAGE: Capsules and solution should be stored at room temperature, 15C to 30 C (59 F to 86F). The oral solution may be refrigerated but should not be frozen.
PRESCRIBED FOR: Abacavir is used in combination with other anti-HIV drugs for the treatment of HIV infection.
DOSING: The recommended dose for adults is 300 mg twice daily or 600 mg once daily. Children (3 months and older) should receive 8 mg/kg twice daily of the solution, and the maximum recommended dose is 300 mg twice daily. Pediatric patients weighing 14 kg or more may also be treated with abacavir tablets at doses of 300, 450, or 600 mg daily based on weight. Abacavir may be administered with or without food since food does not affect its absorption.
DRUG INTERACTIONS: Alcohol competes with abacavir for elimination from the body. Therefore, alcohol consumption may increase the concentration of abacavir in the body, and this could lead to increased frequency or severity of side effects from abacavir. Abacavir does not affect the elimination of alcohol.
PREGNANCY: Use of abacavir during pregnancy has not been adequately evaluated.
NURSING MOTHERS: It is not known whether abacavir is excreted in breast milk. HIV infected mothers should not breast feed because of the potential risk of transmitting HIV to an infant that is not infected.
SIDE EFFECTS: The most common side effects are nausea, vomiting, headache, fatigue, allergic reactions, diarrhea, loss of appetite, and difficulty sleeping. Muscle pain, increased triglyceride levels, rash, anxiety, depression, and fever may also occur. The most serious side effects are severe allergic reactions, pancreatitis, liver failure, and metabolic disturbance (lactic acidosis). Symptoms of an allergic reaction include skin rash, fever, weakness, swelling and difficulty breathing. Abacavir must be stopped as soon an allergic reaction is suspected, and it should not be restarted after an allergic reaction.
Reference: FDA Prescribing Information
Last Editorial Review: 9/6/2012
Back to Medications Index
Get the latest health and medical information delivered direct to your inbox FREE!